CDKN2A and neoplasm: As the results showed, patients with high-risk scores suffered a higher possibility of genetic mutations, KRAS, TP53, SMAD4, CDKN2A, and TTN were the first five genes with the uppermost mutation frequency both in the high/low-risk groups, and the differences of tumor mutation patterns were also exhibited in Figure 10A.